25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Genprex Inc
Buy, Hold or Sell?

Let's analyze Genprex together

I guess you are interested in Genprex Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Genprex Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Genprex Inc

I send you an email if I find something interesting about Genprex Inc.

1. Quick Overview

1.1. Quick analysis of Genprex (30 sec.)










1.2. What can you expect buying and holding a share of Genprex? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.20
Expected worth in 1 year
$-1.05
How sure are you?
27.8%

+ What do you gain per year?

Total Gains per Share
$-1.25
Return On Investment
-107.8%

For what price can you sell your share?

Current Price per Share
$1.16
Expected price per share
$0.43 - $3.8797
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Genprex (5 min.)




Live pricePrice per Share (EOD)
$1.16
Intrinsic Value Per Share
$-22.73 - $-26.60
Total Value Per Share
$-22.53 - $-26.40

2.2. Growth of Genprex (5 min.)




Is Genprex growing?

Current yearPrevious yearGrowGrow %
How rich?$1.6m$16.2m-$10.7m-193.5%

How much money is Genprex making?

Current yearPrevious yearGrowGrow %
Making money-$5.6m-$7.8m$2.1m37.7%
Net Profit Margin-6,444.7%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Genprex (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#762 / 944

Most Revenue
#759 / 944

Most Profit
#457 / 944

Most Efficient
#843 / 944
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Genprex?

Welcome investor! Genprex's management wants to use your money to grow the business. In return you get a share of Genprex.

First you should know what it really means to hold a share of Genprex. And how you can make/lose money.

Speculation

The Price per Share of Genprex is $1.16. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Genprex.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Genprex, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.20. Based on the TTM, the Book Value Change Per Share is $-0.31 per quarter. Based on the YOY, the Book Value Change Per Share is $0.22 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Genprex.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.51-43.7%-0.67-57.5%-0.96-82.8%-0.39-34.0%-0.28-24.6%
Usd Book Value Change Per Share-0.32-27.2%-0.31-27.0%0.2218.8%0.00-0.1%0.010.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.32-27.2%-0.31-27.0%0.2218.8%0.00-0.1%0.010.5%
Usd Price Per Share0.36-1.36-0.93-1.96-1.63-
Price to Earnings Ratio-0.18--0.48--0.24--3.65--2.99-
Price-to-Total Gains Ratio-1.15-3.43-2.65--7.00--12.19-
Price to Book Ratio1.85-2.17-0.48-2.54-5.63-
Price-to-Total Gains Ratio-1.15-3.43-2.65--7.00--12.19-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.16
Number of shares862
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.310.00
Usd Total Gains Per Share-0.310.00
Gains per Quarter (862 shares)-269.51-1.18
Gains per Year (862 shares)-1,078.05-4.71
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1078-10880-5-15
20-2156-21660-9-20
30-3234-32440-14-25
40-4312-43220-19-30
50-5390-54000-24-35
60-6468-64780-28-40
70-7546-75560-33-45
80-8624-86340-38-50
90-9702-97120-42-55
100-10781-107900-47-60

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%1.035.00.02.8%1.035.00.02.8%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%6.014.00.030.0%10.022.04.027.8%10.022.04.027.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.036.00.0%0.00.036.00.0%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%6.014.00.030.0%10.022.04.027.8%10.022.04.027.8%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Genprex Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.315-0.313-1%0.218-244%-0.001-100%0.005-5896%
Book Value Per Share--0.1960.652-70%1.913-90%0.963-80%0.644-70%
Current Ratio--0.8551.885-55%4.483-81%26.355-97%18.830-95%
Debt To Asset Ratio--0.5740.381+51%0.206+179%0.143+301%0.145+295%
Debt To Equity Ratio--1.3470.685+97%0.265+408%0.218+518%0.248+443%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--2323355.91911756683.142-80%19092190.110-88%86786153.554-97%75675522.167-97%
Eps---0.507-0.667+32%-0.960+89%-0.395-22%-0.285-44%
Ev To Ebitda Ratio---0.134inf+inf%-0.618+360%inf+inf%inf+inf%
Ev To Sales Ratio--infnannan%infnan%nannan%nannan%
Free Cash Flow Per Share---0.255-0.536+110%-0.718+182%-0.307+20%-0.207-19%
Free Cash Flow To Equity Per Share---0.112-0.300+168%-0.215+92%-0.062-45%-0.027-76%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---26.600--------
Intrinsic Value_10Y_min---22.728--------
Intrinsic Value_1Y_max---1.917--------
Intrinsic Value_1Y_min---1.882--------
Intrinsic Value_3Y_max---6.330--------
Intrinsic Value_3Y_min---6.031--------
Intrinsic Value_5Y_max---11.431--------
Intrinsic Value_5Y_min---10.561--------
Market Cap9869361.200+69%3077368.91911606496.392-73%7877196.610-61%67313356.154-95%44750343.903-93%
Net Profit Margin----64.4470%-0%-12.8890%-7.1610%
Operating Margin----64.7480%-0%-12.9500%-7.1940%
Operating Ratio---64.748-100%-0%12.950-100%7.194-100%
Pb Ratio5.928+69%1.8482.175-15%0.479+286%2.544-27%5.634-67%
Pe Ratio-0.572-221%-0.178-0.485+172%-0.242+36%-3.653+1949%-2.990+1577%
Price Per Share1.160+69%0.3621.364-73%0.926-61%1.963-82%1.627-78%
Price To Free Cash Flow Ratio-1.138-221%-0.355-0.585+65%-0.343-3%-4.630+1205%-5.009+1312%
Price To Total Gains Ratio-3.682-221%-1.1483.433-133%2.652-143%-7.005+510%-12.191+962%
Quick Ratio--0.6640.978-32%4.295-85%24.270-97%17.013-96%
Return On Assets---1.105-0.780-29%-0.404-63%-0.351-68%-0.661-40%
Return On Equity---2.592-1.392-46%-0.518-80%-0.505-81%-0.845-67%
Total Gains Per Share---0.315-0.313-1%0.218-244%-0.001-100%0.005-5896%
Usd Book Value--1664971.0005545896.250-70%16278991.500-90%23707092.350-93%14753115.472-89%
Usd Book Value Change Per Share---0.315-0.313-1%0.218-244%-0.001-100%0.005-5896%
Usd Book Value Per Share--0.1960.652-70%1.913-90%0.963-80%0.644-70%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--2323355.91911756683.142-80%19092190.110-88%86786153.554-97%75675522.167-97%
Usd Eps---0.507-0.667+32%-0.960+89%-0.395-22%-0.285-44%
Usd Free Cash Flow---2168937.000-4559134.750+110%-6110613.500+182%-4420496.619+104%-2960825.288+37%
Usd Free Cash Flow Per Share---0.255-0.536+110%-0.718+182%-0.307+20%-0.207-19%
Usd Free Cash Flow To Equity Per Share---0.112-0.300+168%-0.215+92%-0.062-45%-0.027-76%
Usd Market Cap9869361.200+69%3077368.91911606496.392-73%7877196.610-61%67313356.154-95%44750343.903-93%
Usd Price Per Share1.160+69%0.3621.364-73%0.926-61%1.963-82%1.627-78%
Usd Profit---4315987.000-5677488.250+32%-7817120.000+81%-5544094.150+28%-3924815.389-9%
Usd Revenue---5788.500-100%-0%1157.700-100%643.167-100%
Usd Total Gains Per Share---0.315-0.313-1%0.218-244%-0.001-100%0.005-5896%
 EOD+5 -3MRQTTM+12 -22YOY+11 -215Y+9 -2510Y+6 -28

3.3 Fundamental Score

Let's check the fundamental score of Genprex Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.572
Price to Book Ratio (EOD)Between0-15.928
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.664
Current Ratio (MRQ)Greater than10.855
Debt to Asset Ratio (MRQ)Less than10.574
Debt to Equity Ratio (MRQ)Less than11.347
Return on Equity (MRQ)Greater than0.15-2.592
Return on Assets (MRQ)Greater than0.05-1.105
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of Genprex Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.375
Ma 20Greater thanMa 501.130
Ma 50Greater thanMa 1001.304
Ma 100Greater thanMa 2001.053
OpenGreater thanClose1.070
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Genprex Inc

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Fundamental data was last updated by Penke on 2024-12-05 21:06:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Genprex earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Genprex to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Genprex Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-6,444.7%+6,444.7%
TTM-6,444.7%YOY--6,444.7%
TTM-6,444.7%5Y-1,288.9%-5,155.8%
5Y-1,288.9%10Y-716.1%-572.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--108.6%+108.6%
TTM-6,444.7%-221.4%-6,223.3%
YOY--207.4%+207.4%
5Y-1,288.9%-346.2%-942.7%
10Y-716.1%-470.4%-245.7%
4.3.1.2. Return on Assets

Shows how efficient Genprex is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Genprex to the Biotechnology industry mean.
  • -110.5% Return on Assets means that Genprex generated $-1.10 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Genprex Inc:

  • The MRQ is -110.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -78.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-110.5%TTM-78.0%-32.5%
TTM-78.0%YOY-40.4%-37.6%
TTM-78.0%5Y-35.1%-42.9%
5Y-35.1%10Y-66.1%+31.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-110.5%-11.6%-98.9%
TTM-78.0%-12.0%-66.0%
YOY-40.4%-11.2%-29.2%
5Y-35.1%-12.6%-22.5%
10Y-66.1%-14.1%-52.0%
4.3.1.3. Return on Equity

Shows how efficient Genprex is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Genprex to the Biotechnology industry mean.
  • -259.2% Return on Equity means Genprex generated $-2.59 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Genprex Inc:

  • The MRQ is -259.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -139.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-259.2%TTM-139.2%-120.0%
TTM-139.2%YOY-51.8%-87.4%
TTM-139.2%5Y-50.5%-88.7%
5Y-50.5%10Y-84.5%+34.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-259.2%-14.5%-244.7%
TTM-139.2%-16.0%-123.2%
YOY-51.8%-14.6%-37.2%
5Y-50.5%-18.5%-32.0%
10Y-84.5%-19.2%-65.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Genprex Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Genprex is operating .

  • Measures how much profit Genprex makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Genprex to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Genprex Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-6,474.8%+6,474.8%
TTM-6,474.8%YOY--6,474.8%
TTM-6,474.8%5Y-1,295.0%-5,179.9%
5Y-1,295.0%10Y-719.4%-575.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--204.0%+204.0%
TTM-6,474.8%-316.8%-6,158.0%
YOY--215.6%+215.6%
5Y-1,295.0%-376.1%-918.9%
10Y-719.4%-480.3%-239.1%
4.3.2.2. Operating Ratio

Measures how efficient Genprex is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Genprex Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM64.748-64.748
TTM64.748YOY-+64.748
TTM64.7485Y12.950+51.799
5Y12.95010Y7.194+5.755
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.284-2.284
TTM64.7483.198+61.550
YOY-3.247-3.247
5Y12.9504.651+8.299
10Y7.1946.419+0.775
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Genprex Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Genprex is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.86 means the company has $0.86 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Genprex Inc:

  • The MRQ is 0.855. The company is just not able to pay all its short-term debts. -1
  • The TTM is 1.885. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ0.855TTM1.885-1.029
TTM1.885YOY4.483-2.599
TTM1.8855Y26.355-24.471
5Y26.35510Y18.830+7.525
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8553.586-2.731
TTM1.8853.869-1.984
YOY4.4834.644-0.161
5Y26.3555.971+20.384
10Y18.8306.240+12.590
4.4.3.2. Quick Ratio

Measures if Genprex is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Genprex to the Biotechnology industry mean.
  • A Quick Ratio of 0.66 means the company can pay off $0.66 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Genprex Inc:

  • The MRQ is 0.664. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.978. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.664TTM0.978-0.314
TTM0.978YOY4.295-3.318
TTM0.9785Y24.270-23.293
5Y24.27010Y17.013+7.257
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6643.093-2.429
TTM0.9783.392-2.414
YOY4.2954.304-0.009
5Y24.2705.953+18.317
10Y17.0136.435+10.578
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Genprex Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Genprex assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Genprex to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.57 means that Genprex assets are financed with 57.4% credit (debt) and the remaining percentage (100% - 57.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Genprex Inc:

  • The MRQ is 0.574. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.381. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.574TTM0.381+0.193
TTM0.381YOY0.206+0.175
TTM0.3815Y0.143+0.238
5Y0.14310Y0.145-0.002
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5740.346+0.228
TTM0.3810.347+0.034
YOY0.2060.313-0.107
5Y0.1430.365-0.222
10Y0.1450.383-0.238
4.5.4.2. Debt to Equity Ratio

Measures if Genprex is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Genprex to the Biotechnology industry mean.
  • A Debt to Equity ratio of 134.7% means that company has $1.35 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Genprex Inc:

  • The MRQ is 1.347. The company is able to pay all its debts with equity. +1
  • The TTM is 0.685. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ1.347TTM0.685+0.662
TTM0.685YOY0.265+0.420
TTM0.6855Y0.218+0.467
5Y0.21810Y0.248-0.030
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3470.393+0.954
TTM0.6850.432+0.253
YOY0.2650.388-0.123
5Y0.2180.455-0.237
10Y0.2480.498-0.250
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Genprex generates.

  • Above 15 is considered overpriced but always compare Genprex to the Biotechnology industry mean.
  • A PE ratio of -0.18 means the investor is paying $-0.18 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Genprex Inc:

  • The EOD is -0.572. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.178. Based on the earnings, the company is expensive. -2
  • The TTM is -0.485. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.572MRQ-0.178-0.393
MRQ-0.178TTM-0.485+0.307
TTM-0.485YOY-0.242-0.243
TTM-0.4855Y-3.653+3.168
5Y-3.65310Y-2.990-0.663
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.572-2.180+1.608
MRQ-0.178-2.507+2.329
TTM-0.485-3.153+2.668
YOY-0.242-3.242+3.000
5Y-3.653-5.992+2.339
10Y-2.990-6.690+3.700
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Genprex Inc:

  • The EOD is -1.138. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.355. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.585. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.138MRQ-0.355-0.783
MRQ-0.355TTM-0.585+0.230
TTM-0.585YOY-0.343-0.242
TTM-0.5855Y-4.630+4.046
5Y-4.63010Y-5.009+0.378
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.138-2.879+1.741
MRQ-0.355-3.276+2.921
TTM-0.585-3.669+3.084
YOY-0.343-4.485+4.142
5Y-4.630-8.015+3.385
10Y-5.009-9.197+4.188
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Genprex is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.85 means the investor is paying $1.85 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Genprex Inc:

  • The EOD is 5.928. Based on the equity, the company is overpriced. -1
  • The MRQ is 1.848. Based on the equity, the company is underpriced. +1
  • The TTM is 2.175. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD5.928MRQ1.848+4.079
MRQ1.848TTM2.175-0.326
TTM2.175YOY0.479+1.696
TTM2.1755Y2.544-0.369
5Y2.54410Y5.634-3.090
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.9281.964+3.964
MRQ1.8482.056-0.208
TTM2.1752.388-0.213
YOY0.4792.460-1.981
5Y2.5443.697-1.153
10Y5.6344.324+1.310
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Genprex Inc.

4.8.1. Institutions holding Genprex Inc

Institutions are holding 10.908% of the shares of Genprex Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30UBS Group AG0.66240563595626861832.967
2024-09-30TWO SIGMA SECURITIES, LLC0.27080.000123040230400
2024-09-30HighTower Advisors, LLC0.2471021027210270
2024-09-30Geode Capital Management, LLC0.191016247-250-1.5154
2024-09-30HRT FINANCIAL LLC0.1827015540155400
2024-09-30Vanguard Group Inc0.1801531500
2024-06-30BlackRock Inc0.133901139400
2024-09-30Tower Research Capital LLC0.1090.000192715375137.962
2024-09-30Morgan Stanley - Brokerage Accounts0.018501574-1400-47.0746
2024-06-30Bank of America Corp0.0050429163.8741
2024-09-30Aspire Private Capital, LLC0.004704004000
2024-09-30ASHTON THOMAS SECURITIES, LLC0.001501271270
2024-09-30Hanson Mcclain Inc0.001501251250
2024-09-30Group One Trading, LP0.00130114-714-86.2319
2024-09-30Royal Bank of Canada0.000706300
2024-09-30VitalStone Financial LLC0.000101000
2024-09-30Global Retirement Partners, LLC.0.00010500
2024-09-30JPMorgan Chase & Co0.00010500
2024-06-30Wells Fargo & Co000-11-100
2024-06-30Financial Gravity Wealth, Inc.000-21-100
Total 2.01040.0002171045+119522+69.9%

4.9.2. Funds holding Genprex Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-10-31Vanguard Institutional Extnd Mkt Idx Tr0.17601497500
2024-09-30Fidelity Extended Market Index0.135201150000
2024-09-30Fidelity Total Market Index0.020170300
2024-09-30EC SICAV EverCapital Invms UCITS I Ins I0.01760.0053150000
2024-09-30Fidelity Series Total Market Index0.0160136300
2024-09-30NT Ext Equity Mkt Idx Fd - NL0.01190100900
2024-09-30NT Ext Equity Mkt Idx Fd - L0.0107091300
2024-09-30Northern Trust Extended Eq Market Idx0.0107091300
2024-09-30Fidelity Nasdaq Composite Index0.0103087900
2024-09-30NT Ext Equity Mkt Idx Fd - DC - NL - T20.0096081320.2466
2024-09-30Spartan Total Market Index Pool E0.0093079200
2024-10-31State St US Extended Mkt Indx NL Cl C0.00460.000139500
2024-10-31Vanguard U.S. Eq Idx £ Acc0.004034000
2024-09-30BNYM Mellon SL Market Completion UC10.0039033100
2024-06-30SSgA U.S. Total Market Index Strategy0.001901624842.1053
2024-09-30NT Ext Eq Mkt Indx Fd DC Lending Tier 50.0017014100
2024-10-31State St US Ttl Mkt Indx SL Cl I0.0014012000
2024-09-30Northern Trust Wilshire 50000.0014011800
2024-09-30Fidelity U.S. Equity Index Ins Trust0.000101000
2024-09-30BNYM Mellon NSL Mkt Completion Fund Inst00400
Total 0.44630.005437981+50+0.1%

5.3. Insider Transactions

Insiders are holding 6.403% of the shares of Genprex Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-04-21Catherine M VaczyBUY50042.8
2023-04-21John Rodney VarnerBUY47542
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-09-302023-12-312024-03-312024-06-302024-09-30
Net Working Capital  8,519-4,2414,2781,1425,420-3,2842,136-2,460-325



5.2. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets3,907
Total Liabilities2,242
Total Stockholder Equity1,665
 As reported
Total Liabilities 2,242
Total Stockholder Equity+ 1,665
Total Assets = 3,907

Assets

Total Assets3,907
Total Current Assets1,918
Long-term Assets1,990
Total Current Assets
Cash And Cash Equivalents 1,488
Other Current Assets 429
Total Current Assets  (as reported)1,918
Total Current Assets  (calculated)1,918
+/-0
Long-term Assets
Property Plant Equipment 0
Long-term Assets Other 1,989
Long-term Assets  (as reported)1,990
Long-term Assets  (calculated)1,990
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities2,242
Long-term Liabilities0
Total Stockholder Equity1,665
Total Current Liabilities
Accounts payable 1,304
Other Current Liabilities 938
Total Current Liabilities  (as reported)2,242
Total Current Liabilities  (calculated)2,242
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock5
Retained Earnings -150,469
Other Stockholders Equity 152,128
Total Stockholder Equity (as reported)1,665
Total Stockholder Equity (calculated)1,665
+/-0
Other
Cash and Short Term Investments 1,488
Common Stock Shares Outstanding 3,500
Liabilities and Stockholders Equity 3,907
Net Debt -1,488
Net Working Capital -325



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
> Total Assets 
410
0
0
0
1,911
1,277
1,008
1,267
1,267
1,260
12,891
11,049
9,269
9,269
6,264
4,068
3,534
24,640
24,749
23,352
31,367
51,036
48,731
46,327
42,862
39,409
34,565
29,946
25,085
23,320
15,911
16,644
10,671
12,565
6,605
3,907
3,9076,60512,56510,67116,64415,91123,32025,08529,94634,56539,40942,86246,32748,73151,03631,36723,35224,74924,6403,5344,0686,2649,2699,26911,04912,8911,2601,2671,2671,0081,2771,911000410
   > Total Current Assets 
250
0
0
0
1,639
954
496
401
401
194
12,540
10,689
8,847
8,847
5,802
3,609
2,977
24,032
24,158
22,711
30,715
50,378
48,062
45,645
39,140
35,703
30,901
26,308
21,473
19,942
12,366
12,857
7,532
9,228
4,395
1,918
1,9184,3959,2287,53212,85712,36619,94221,47326,30830,90135,70339,14045,64548,06250,37830,71522,71124,15824,0322,9773,6095,8028,8478,84710,68912,5401944014014969541,639000250
       Cash And Cash Equivalents 
234
0
0
0
1,602
930
468
374
374
161
12,002
10,310
8,601
8,601
4,497
2,548
2,002
23,080
22,127
21,058
27,320
47,069
44,243
42,021
38,629
34,555
30,053
25,516
20,954
18,083
9,956
11,711
6,738
8,217
2,459
1,488
1,4882,4598,2176,73811,7119,95618,08320,95425,51630,05334,55538,62942,02144,24347,06927,32021,05822,12723,0802,0022,5484,4978,6018,60110,31012,0021613743744689301,602000234
       Net Receivables 
0
0
0
0
8
0
0
0
9
9
0
9
9
9
11
0
1
1
0
0
0
0
0
0
0
32
0
35
35
3,359
0
0
0
0
0
0
0000003,359353503200000001101199909900080000
       Other Current Assets 
16
0
0
0
37
24
28
27
23
23
539
370
237
237
849
259
172
70
1,136
966
385
201
756
749
511
1,116
848
757
484
1,859
2,410
1,146
794
1,011
1,936
429
4291,9361,0117941,1462,4101,8594847578481,1165117497562013859661,1367017225984923723737053923232728243700016
   > Long-term Assets 
0
0
0
0
272
322
512
866
866
1,066
351
360
422
422
462
459
558
608
592
641
652
659
670
682
3,722
3,706
3,664
3,638
3,612
3,378
3,545
3,787
3,139
3,337
2,210
1,990
1,9902,2103,3373,1393,7873,5453,3783,6123,6383,6643,7063,7226826706596526415926085584594624224223603511,0668668665123222720000
       Property Plant Equipment 
1
0
0
0
5
7
10
9
8
8
14
16
24
24
24
24
45
51
46
42
39
37
39
44
49
42
35
29
23
19
15
11
8
4
2
0
02481115192329354249443937394246514524242424161488910750001
       Goodwill 
0
0
0
0
0
0
0
560
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000005600000000
       Intangible Assets 
156
0
0
0
241
261
277
297
297
299
323
326
379
379
421
424
491
536
535
588
602
611
620
627
642
644
666
682
702
722
742
763
773
790
0
0
00790773763742722702682666644642627620611602588535536491424421379379326323299297297277261241000156
       Long-term Assets Other 
0
0
0
0
26
54
225
560
1,058
760
13
18
398
18
16
12
22
22
11
11
11
11
11
11
3,031
3,020
2,963
2,926
2,887
2,637
2,788
3,012
2,347
2,542
2,208
1,989
1,9892,2082,5422,3473,0122,7882,6372,8872,9262,9633,0203,031111111111111222212161839818137601,05856022554260000
> Total Liabilities 
16
0
0
0
286
170
210
395
395
831
301
565
388
388
939
537
511
697
240
376
451
614
1,047
1,162
1,585
2,385
2,154
2,457
2,810
4,835
3,860
4,338
3,254
3,808
2,259
2,242
2,2422,2593,8083,2544,3383,8604,8352,8102,4572,1542,3851,5851,1621,04761445137624069751153793938838856530183139539521017028600016
   > Total Current Liabilities 
16
0
0
0
286
170
210
395
395
831
301
565
388
388
939
537
511
697
240
376
451
614
1,047
1,162
1,585
2,385
2,154
2,457
2,810
4,835
3,860
4,338
3,254
3,808
2,259
2,242
2,2422,2593,8083,2544,3383,8604,8352,8102,4572,1542,3851,5851,1621,04761445137624069751153793938838856530183139539521017028600016
       Short-term Debt 
0
0
0
0
0
0
0
0
0
279
0
0
0
25
61
62
74
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000074626125000279000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
279
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000279000000000
       Accounts payable 
16
0
0
0
286
139
168
363
629
1,149
301
565
295
206
877
475
436
638
182
321
193
339
370
592
973
1,253
683
684
443
2,212
1,498
1,179
1,398
2,152
1,175
1,304
1,3041,1752,1521,3981,1791,4982,2124436846831,2539735923703391933211826384364758772062955653011,14962936316813928600016
       Other Current Liabilities 
0
0
0
0
286
170
210
395
202
831
301
565
93
388
939
537
511
697
240
54
258
614
677
570
612
1,132
1,471
1,773
2,367
2,623
2,362
3,159
1,857
1,656
1,084
938
9381,0841,6561,8573,1592,3622,6232,3671,7731,4711,13261257067761425854240697511537939388935653018312023952101702860000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
973
1,253
683
684
443
2,212
0
0
0
0
0
0
0000002,2124436846831,253973000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
26
0
225
560
760
1,012
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000001,0127605602250260000
> Total Stockholder Equity
394
0
0
0
1,625
1,107
798
872
429
429
12,590
10,484
8,881
8,881
5,325
3,531
3,024
23,943
24,510
22,976
30,916
50,423
47,684
45,165
41,277
37,025
32,411
27,489
22,275
18,485
12,051
12,305
7,416
8,757
4,346
1,665
1,6654,3468,7577,41612,30512,05118,48522,27527,48932,41137,02541,27745,16547,68450,42330,91622,97624,51023,9433,0243,5315,3258,8818,88110,48412,5904294298727981,1071,625000394
   Common Stock
0
0
0
0
0
0
0
0
12
12
14
15
15
15
16
16
19
33
39
39
43
47
48
48
48
48
48
48
48
52
52
59
0
2
3
5
532059525248484848484848474339393319161615151514121200000000
   Retained Earnings Total Equity00000-120,011-112,0310-94,992-88,910000-68,898-64,912-58,422-53,194-50,419-46,046-40,479-38,054-35,679-31,984-29,825-26,394-24,208-18,146-17,452-16,7860000000
   Accumulated Other Comprehensive Income 000000000000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
17,656
17,869
18,093
36,784
36,863
38,691
39,213
40,988
41,570
43,484
69,956
74,890
76,130
89,296
115,287
116,535
0
0
0
121,273
122,433
0
130,463
132,010
0
0
0
0
0
00000132,010130,4630122,433121,273000116,535115,28789,29676,13074,89069,95643,48441,57040,98839,21338,69136,86336,78418,09317,86917,6560000000
   Treasury Stock000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
15,761
15,995
16,867
17,656
0
17,869
36,784
36,863
0
38,691
40,988
41,570
43,484
69,956
74,890
76,130
89,296
115,287
116,535
117,453
119,247
120,717
121,273
122,433
125,054
130,463
132,010
140,005
0
148,412
150,496
152,128
152,128150,496148,4120140,005132,010130,463125,054122,433121,273120,717119,247117,453116,535115,28789,29676,13074,89069,95643,48441,57040,98838,691036,86336,78417,869017,65616,86715,99515,7610000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-15
Gross Profit-15-15
 
Operating Income (+$)
Gross Profit-15
Operating Expense-31,061
Operating Income-31,076-31,076
 
Operating Expense (+$)
Research Development17,617
Selling General Administrative13,444
Selling And Marketing Expenses13,431
Operating Expense31,06144,491
 
Net Interest Income (+$)
Interest Income231
Interest Expense-0
Other Finance Cost-0
Net Interest Income231
 
Pretax Income (+$)
Operating Income-31,076
Net Interest Income231
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-30,860-31,291
EBIT - interestExpense = -31,076
-30,860
-30,860
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-31,076-30,860
Earnings Before Interest and Taxes (EBITDA)-31,061
 
After tax Income (+$)
Income Before Tax-30,860
Tax Provision-0
Net Income From Continuing Ops-31,455-30,860
Net Income-30,860
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses31,076
Total Other Income/Expenses Net215-231
 

Technical Analysis of Genprex
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Genprex. The general trend of Genprex is BEARISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Genprex's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-28.6%) Bearish trend (28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Genprex Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.25 < 2.35 < 3.8797.

The bearish price targets are: 0.99 > 0.8 > 0.43.

Tweet this
Genprex Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Genprex Inc. The current mas is .

The long score for the Moving Averages is 5/14.
The longshort score for the Moving Averages is -4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Genprex Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Genprex Inc. The current macd is -0.09177262.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Genprex price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Genprex. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Genprex price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Genprex Inc Daily Moving Average Convergence/Divergence (MACD) ChartGenprex Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Genprex Inc. The current adx is 17.67.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Genprex shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Genprex Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Genprex Inc. The current sar is 0.99.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Genprex Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Genprex Inc. The current rsi is 48.37. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Genprex Inc Daily Relative Strength Index (RSI) ChartGenprex Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Genprex Inc. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Genprex price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Genprex Inc Daily Stochastic Oscillator ChartGenprex Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Genprex Inc. The current cci is 7.9239076.

Genprex Inc Daily Commodity Channel Index (CCI) ChartGenprex Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Genprex Inc. The current cmo is 2.06888651.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Genprex Inc Daily Chande Momentum Oscillator (CMO) ChartGenprex Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Genprex Inc. The current willr is -32.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Genprex is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Genprex Inc Daily Williams %R ChartGenprex Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Genprex Inc.

Genprex Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Genprex Inc. The current atr is 0.17926219.

Genprex Inc Daily Average True Range (ATR) ChartGenprex Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Genprex Inc. The current obv is 493,390,091.

Genprex Inc Daily On-Balance Volume (OBV) ChartGenprex Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Genprex Inc. The current mfi is 59.91.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Genprex Inc Daily Money Flow Index (MFI) ChartGenprex Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Genprex Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

<
DateIndicatorSignal
2024-07-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-07-29CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-08-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-12STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-13BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-08-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-09-06CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-11STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-09-12STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-09-13MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-09-16STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-09-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-09-24MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-09-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-16RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-21ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-23STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-24RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-28STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-11-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-18STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-03MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-12-04STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-09STOCH